BACKGROUND AND PURPOSE: As treatment results for high-risk soft tissue sarcoma are still disappointing, treatment intensification is warranted. We performed a retrospective analysis of multimodal preoperative treatment to evaluate the additional effect of concurrent chemotherapy and/or locoregional hyperthermia in comparison to radiotherapy alone. PATIENTS AND METHODS: Between 1999 and 2011, 28 patients were treated with neoadjuvant radiotherapy to a median 45 Gy for high-risk soft tissue sarcoma. All tumors were deep-seated and grade 2 or 3, 86% (n = 24) larger than 5 cm. Multimodal treatment (n = 12) consisted of ifosfamide (n = 7), locoregional hyperthermia (n = 3), or both modalities (n = 2) concurrent to radiotherapy. RESULTS: Prognostic factors (grade, size, histology, location) were balanced in the groups with and without concurrent multimodal treatment. There was a significant improvement of disease-specific survival (100% vs. 70% at 3 years, p = 0.03) with multimodal treatment. Distant metastases-free survival was influenced, but was not statistically significant. Local control and disease-free survival did not differ in the two groups. CONCLUSION: Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas.
BACKGROUND AND PURPOSE: As treatment results for high-risk soft tissue sarcoma are still disappointing, treatment intensification is warranted. We performed a retrospective analysis of multimodal preoperative treatment to evaluate the additional effect of concurrent chemotherapy and/or locoregional hyperthermia in comparison to radiotherapy alone. PATIENTS AND METHODS: Between 1999 and 2011, 28 patients were treated with neoadjuvant radiotherapy to a median 45 Gy for high-risk soft tissue sarcoma. All tumors were deep-seated and grade 2 or 3, 86% (n = 24) larger than 5 cm. Multimodal treatment (n = 12) consisted of ifosfamide (n = 7), locoregional hyperthermia (n = 3), or both modalities (n = 2) concurrent to radiotherapy. RESULTS: Prognostic factors (grade, size, histology, location) were balanced in the groups with and without concurrent multimodal treatment. There was a significant improvement of disease-specific survival (100% vs. 70% at 3 years, p = 0.03) with multimodal treatment. Distant metastases-free survival was influenced, but was not statistically significant. Local control and disease-free survival did not differ in the two groups. CONCLUSION: Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas.
Authors: L R Prosnitz; P Maguire; J M Anderson; S P Scully; J M Harrelson; E L Jones; M Dewhirst; T V Samulski; B E Powers; G L Rosner; R K Dodge; L Layfield; R Clough; D M Brizel Journal: Int J Radiat Oncol Biol Phys Date: 1999-11-01 Impact factor: 7.038
Authors: J N Cormier; S R Patel; C E Herzog; M T Ballo; M A Burgess; B W Feig; K K Hunt; R B Raney; G K Zagars; R S Benjamin; P W Pisters Journal: Cancer Date: 2001-09-15 Impact factor: 6.860
Authors: Thomas F DeLaney; Ira J Spiro; Herman D Suit; Mark C Gebhardt; Francis J Hornicek; Henry J Mankin; Andrew L Rosenberg; Daniel I Rosenthal; Fariba Miryousefi; Marcus Ancukiewicz; David C Harmon Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-15 Impact factor: 7.038
Authors: Kelly K Curtis; Jonathan B Ashman; Christopher P Beauchamp; Adam J Schwartz; Matthew D Callister; Amylou C Dueck; Leonard L Gunderson; Tom R Fitch Journal: Radiat Oncol Date: 2011-08-09 Impact factor: 3.481
Authors: Felipe A Calvo; Claudio V Sole; Alfredo Polo; Mauricio Cambeiro; Angel Montero; Ana Alvarez; Miguel Cuervo; Mikel San Julian; Rafael Martinez-Monge Journal: Strahlenther Onkol Date: 2014-04-09 Impact factor: 3.621
Authors: Vlatko Potkrajcic; Frank Traub; Barbara Hermes; Marcus Scharpf; Jonas Kolbenschlag; Daniel Zips; Frank Paulsen; Franziska Eckert Journal: Radiol Oncol Date: 2021-11-19 Impact factor: 2.991